TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. AU - Ferlay, J. AU - Lortet-Tieulent, J. AU - Jemal, A. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Serrano, N. A. AU - Anscher, M. S. PY - 2016 DA - 2016// TI - Favorable vs unfavorable intermediate-risk prostate cancer: a review of the new classification system and its impact on treatment recommendations JO - Oncology (Williston Park) VL - 30 ID - Serrano2016 ER - TY - JOUR AU - Thomsen, F. B. AU - Mikkelsen, M. K. AU - Hansen, R. B. PY - 2016 DA - 2016// TI - Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center JO - Acta Oncol VL - 55 UR - https://doi.org/10.1080/0284186X.2016.1191667 DO - 10.1080/0284186X.2016.1191667 ID - Thomsen2016 ER - TY - JOUR AU - D'Amico, A. V. AU - Chen, M. H. AU - Renshaw, A. AU - Loffredo, M. AU - Kantoff, P. W. PY - 2015 DA - 2015// TI - Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer JO - JAMA VL - 314 UR - https://doi.org/10.1001/jama.2015.8577 DO - 10.1001/jama.2015.8577 ID - D'Amico2015 ER - TY - JOUR AU - Pisansky, T. M. AU - Hunt, D. AU - Gomella, L. G. PY - 2015 DA - 2015// TI - Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910 JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.0662 DO - 10.1200/JCO.2014.58.0662 ID - Pisansky2015 ER - TY - JOUR AU - Xu, N. AU - Rossi, P. J. AU - Jani, A. B. PY - 2011 DA - 2011// TI - Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer JO - Am J Clin Oncol VL - 34 UR - https://doi.org/10.1097/COC.0b013e3181cae8c6 DO - 10.1097/COC.0b013e3181cae8c6 ID - Xu2011 ER - TY - JOUR AU - Zelefsky, M. J. AU - Levin, E. J. AU - Hunt, M. PY - 2008 DA - 2008// TI - Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 70 UR - https://doi.org/10.1016/j.ijrobp.2007.11.044 DO - 10.1016/j.ijrobp.2007.11.044 ID - Zelefsky2008 ER - TY - JOUR AU - Eade, T. N. AU - Hanlon, A. L. AU - Horwitz, E. M. AU - Buyyounouski, M. K. AU - Hanks, G. E. AU - Pollack, A. PY - 2007 DA - 2007// TI - What dose of external-beam radiation is high enough for prostate cancer? JO - Int J Radiat Oncol Biol Phys VL - 68 UR - https://doi.org/10.1016/j.ijrobp.2007.01.008 DO - 10.1016/j.ijrobp.2007.01.008 ID - Eade2007 ER - TY - JOUR AU - Miralbell, R. AU - Roberts, S. A. AU - Zubizarreta, E. AU - Hendry, J. H. PY - 2012 DA - 2012// TI - Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy JO - Int J Radiat Oncol Biol Phys VL - 82 UR - https://doi.org/10.1016/j.ijrobp.2010.10.075 DO - 10.1016/j.ijrobp.2010.10.075 ID - Miralbell2012 ER - TY - JOUR AU - Miles, E. F. AU - Lee, W. R. PY - 2008 DA - 2008// TI - Hypofractionation for prostate cancer: a critical review JO - Semin Radiat Oncol VL - 18 UR - https://doi.org/10.1016/j.semradonc.2007.09.006 DO - 10.1016/j.semradonc.2007.09.006 ID - Miles2008 ER - TY - JOUR AU - Kupelian, P. A. AU - Reddy, C. A. AU - Klein, E. A. AU - Willoughby, T. R. PY - 2001 DA - 2001// TI - Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life JO - Int J Radiat Oncol Biol Phys VL - 51 UR - https://doi.org/10.1016/S0360-3016(01)01730-8 DO - 10.1016/S0360-3016(01)01730-8 ID - Kupelian2001 ER - TY - JOUR AU - Arcangeli, G. AU - Fowler, J. AU - Gomellini, S. PY - 2011 DA - 2011// TI - Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 79 UR - https://doi.org/10.1016/j.ijrobp.2009.12.045 DO - 10.1016/j.ijrobp.2009.12.045 ID - Arcangeli2011 ER - TY - JOUR AU - Pollack, A. AU - Walker, G. AU - Horwitz, E. M. PY - 2013 DA - 2013// TI - Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.51.1972 DO - 10.1200/JCO.2013.51.1972 ID - Pollack2013 ER - TY - JOUR AU - Liberati, A. AU - Altman, D. G. AU - Tetzlaff, J. PY - 2009 DA - 2009// TI - The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration JO - Ann Intern Med VL - 151 UR - https://doi.org/10.7326/0003-4819-151-4-200908180-00136 DO - 10.7326/0003-4819-151-4-200908180-00136 ID - Liberati2009 ER - TY - JOUR AU - Tierney, J. F. AU - Stewart, L. A. AU - Ghersi, D. AU - Burdett, S. AU - Sydes, M. R. PY - 2007 DA - 2007// TI - Practical methods for incorporating summary time-to-event data into meta-analysis JO - Trials VL - 8 UR - https://doi.org/10.1186/1745-6215-8-16 DO - 10.1186/1745-6215-8-16 ID - Tierney2007 ER - TY - JOUR AU - Incrocci, L. AU - Wortel, R. C. AU - Alemayehu, W. G. PY - 2016 DA - 2016// TI - Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30070-5 DO - 10.1016/S1470-2045(16)30070-5 ID - Incrocci2016 ER - TY - JOUR AU - Aluwini, S. AU - Pos, F. AU - Schimmel, E. PY - 2016 DA - 2016// TI - Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00567-7 DO - 10.1016/S1470-2045(15)00567-7 ID - Aluwini2016 ER - TY - JOUR AU - Aluwini, S. AU - Pos, F. AU - Schimmel, E. PY - 2015 DA - 2015// TI - Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)70482-6 DO - 10.1016/S1470-2045(14)70482-6 ID - Aluwini2015 ER - TY - JOUR AU - Arcangeli, G. AU - Saracino, B. AU - Gomellini, S. PY - 2010 DA - 2010// TI - A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 78 UR - https://doi.org/10.1016/j.ijrobp.2009.07.1691 DO - 10.1016/j.ijrobp.2009.07.1691 ID - Arcangeli2010 ER - TY - JOUR AU - Arcangeli, S. AU - Strigari, L. AU - Gomellini, S. PY - 2012 DA - 2012// TI - Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 84 UR - https://doi.org/10.1016/j.ijrobp.2012.02.049 DO - 10.1016/j.ijrobp.2012.02.049 ID - Arcangeli2012 ER - TY - JOUR AU - Arcangeli, G. AU - Saracino, B. AU - Arcangeli, S. PY - 2017 DA - 2017// TI - Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.4189 DO - 10.1200/JCO.2016.70.4189 ID - Arcangeli2017 ER - TY - JOUR AU - Pollack, A. AU - Hanlon, A. L. AU - Horwitz, E. M. PY - 2006 DA - 2006// TI - Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial JO - Int J Radiat Oncol Biol Phys VL - 64 UR - https://doi.org/10.1016/j.ijrobp.2005.07.970 DO - 10.1016/j.ijrobp.2005.07.970 ID - Pollack2006 ER - TY - JOUR AU - Marzi, S. AU - Saracino, B. AU - Petrongari, M. G. PY - 2009 DA - 2009// TI - Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer JO - J Exp Clin Cancer Res VL - 28 UR - https://doi.org/10.1186/1756-9966-28-117 DO - 10.1186/1756-9966-28-117 ID - Marzi2009 ER - TY - JOUR AU - Strigari, L. AU - Arcangeli, G. AU - Arcangeli, S. AU - Benassi, M. PY - 2009 DA - 2009// TI - Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 73 UR - https://doi.org/10.1016/j.ijrobp.2008.07.024 DO - 10.1016/j.ijrobp.2008.07.024 ID - Strigari2009 ER - TY - JOUR AU - Catton, C. N. AU - Lukka, H. AU - Gu, C. S. PY - 2017 DA - 2017// TI - Randomized trial of a Hypofractionated radiation regimen for the treatment of localized prostate cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.7397 DO - 10.1200/JCO.2016.71.7397 ID - Catton2017 ER - TY - JOUR AU - Peeters, S. T. AU - Heemsbergen, W. D. AU - Koper, P. C. PY - 2006 DA - 2006// TI - Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.2530 DO - 10.1200/JCO.2005.05.2530 ID - Peeters2006 ER - TY - JOUR AU - Dearnaley, D. P. AU - Jovic, G. AU - Syndikus, I. PY - 2014 DA - 2014// TI - Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70040-3 DO - 10.1016/S1470-2045(14)70040-3 ID - Dearnaley2014 ER - TY - JOUR AU - Denham, J. W. AU - Steigler, A. AU - Joseph, D. PY - 2015 DA - 2015// TI - Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial JO - Radiother Oncol VL - 115 UR - https://doi.org/10.1016/j.radonc.2015.05.016 DO - 10.1016/j.radonc.2015.05.016 ID - Denham2015 ER - TY - JOUR AU - Kuban, D. A. AU - Tucker, S. L. AU - Dong, L. PY - 2008 DA - 2008// TI - Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 70 UR - https://doi.org/10.1016/j.ijrobp.2007.06.054 DO - 10.1016/j.ijrobp.2007.06.054 ID - Kuban2008 ER - TY - JOUR AU - Kalbasi, A. AU - Li, J. AU - Berman, A. PY - 2015 DA - 2015// TI - Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer JO - JAMA Oncol VL - 1 UR - https://doi.org/10.1001/jamaoncol.2015.2316 DO - 10.1001/jamaoncol.2015.2316 ID - Kalbasi2015 ER - TY - JOUR AU - Morgan, S. C. AU - Waldron, T. S. AU - Eapen, L. PY - 2008 DA - 2008// TI - Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis JO - Radiother Oncol VL - 88 UR - https://doi.org/10.1016/j.radonc.2008.04.013 DO - 10.1016/j.radonc.2008.04.013 ID - Morgan2008 ER - TY - JOUR AU - Roach, M. AU - Hanks, G. AU - Thames, H. PY - 2006 DA - 2006// TI - Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference JO - Int J Radiat Oncol Biol Phys VL - 65 UR - https://doi.org/10.1016/j.ijrobp.2006.04.029 DO - 10.1016/j.ijrobp.2006.04.029 ID - Roach2006 ER - TY - JOUR AU - Dearnaley, D. AU - Syndikus, I. AU - Mossop, H. PY - 2016 DA - 2016// TI - Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30102-4 DO - 10.1016/S1470-2045(16)30102-4 ID - Dearnaley2016 ER - TY - JOUR AU - Cao, L. AU - Yang, Y. J. AU - Li, Z. W. PY - 2017 DA - 2017// TI - Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.13735 DO - 10.18632/oncotarget.13735 ID - Cao2017 ER - TY - JOUR AU - Valeriani, M. PY - 2014 DA - 2014// TI - Image-guided hypofractionated radiotherapy in low-risk prostate cancer patients JO - J Biomed Biotechnol VL - 2014 ID - Valeriani2014 ER - TY - JOUR AU - Valeriani, M. PY - 2018 DA - 2018// TI - Moderate hypofractionation in patients with low-risk prostate cancer: long-term outcomes JO - Anticancer Res VL - 38.3 ID - Valeriani2018 ER - TY - STD TI - Bruner DW, et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA Oncol, Epub ahead of print. 2019. ID - ref37 ER - TY - JOUR AU - Yin, Z. Z. AU - You, J. Q. AU - Wang, Y. Y. PY - 2019 DA - 2019// TI - Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from phase III randomized trials JO - Onco Targets Ther VL - 12 UR - https://doi.org/10.2147/OTT.S181067 DO - 10.2147/OTT.S181067 ID - Yin2019 ER - TY - JOUR AU - Carvalho, Í. T. AU - Baccaglini, W. AU - Claros, O. R. PY - 2018 DA - 2018// TI - Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis JO - Acta Oncol VL - 57 UR - https://doi.org/10.1080/0284186X.2018.1478126 DO - 10.1080/0284186X.2018.1478126 ID - Carvalho2018 ER - TY - JOUR AU - Sánchez-Gómez, L. M. AU - Polo-deSantos, M. AU - Rodríguez-Melcón, J. I. PY - 2015 DA - 2015// TI - Hypofractionated radiation therapy versus conventional radiation therapy in prostate cancer: a systematic review of its safety and efficacy JO - Actas Urol Esp VL - 39 UR - https://doi.org/10.1016/j.acuro.2014.12.005 DO - 10.1016/j.acuro.2014.12.005 ID - Sánchez-Gómez2015 ER - TY - JOUR AU - Botrel, T. E. AU - Clark, O. AU - Pompeo, A. C. PY - 2013 DA - 2013// TI - Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis JO - Core Evid VL - 8 UR - https://doi.org/10.2147/CE.S41178 DO - 10.2147/CE.S41178 ID - Botrel2013 ER -